MDM2 and glioblastoma: Furthermore, alterations in the p53 signaling pathway have been reported in glioblastoma, including p14ARF deletions (55%), mdm2 amplification (8–11%), and mdm4 amplification (4%), in addition to mutations in p53 itself [130,131].